Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Inclusion criteria: * Age \>= 18 years * Signed informed consent * Histologically or cytologically confirmed colorectal adenocarcinoma * Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy * Eastern Cooperative Oncology Group (ECOG) performance status = 1 * At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 * Progression on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following: * \- fluoropyrimidine * \- oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease * \- irinotecan * \- bevacizumab or aflibercept * \- cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours * \- The remaining standard available therapy as recommended by investigator is best supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and these agents should be administered before study if available to patient according to local standards) * \- Life expectancy of at least 12 weeks * \- Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT) = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin \< 2 X ULN and normal AST/ALT are eligible * Coagulation parameters: International normalised ratio (INR) \< 2 and partial prothrombin Time (PTT) = 2xULN Exclusion criteria: * Previous treatment with nintedanib * toxicity attributed to previous anticancer therapy that did not resolve to Common Terminology Criteria for Adverse Events (CTCAE) grade =1 * History of other malignancies in the last 5 years, in particular those that could interfere with interpretation of results. * Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, * Significant cardiovascular diseases * History of severe haemorrhagic or thromboembolic event in the past 12 months * Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic INR monitoring * Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug * Patient with brain metastases that are symptomatic and/or require therapy. * Patients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraception * Pregnancy or breast-feeding.